Long-Term Noninvasive Ventilation in the Geneva Lake Area: Indications, Prevalence, and Modalities

Chloé Cantero; Dan Adler; Patrick Pasquina; Christophe Uldry; Bernard Egger; Maura Prella; Alain B Younossian; Paola M Soccal; Jean-Louis Pépin; Jean-Paul Janssens

doi:10.1016/j.chest.2020.02.064

Long-Term Noninvasive Ventilation in the Geneva Lake Area: Indications, Prevalence, and Modalities

Chest. 2020 Jul;158(1):279-291. doi: 10.1016/j.chest.2020.02.064. Epub 2020 Mar 31.

Authors

Affiliations

¹ Division of Pulmonary Diseases, Geneva University Hospitals (HUG), Geneva, Switzerland.
² Division of Pulmonary Diseases, Geneva University Hospitals (HUG), Geneva, Switzerland; Faculty of Medicine, University of Geneva, Geneva, Switzerland.
³ Division of Pulmonary Diseases and Pulmonary Rehabilitation Center, Rolle Hospital Rolle, Vaud, Switzerland.
⁴ Division of Pulmonary Diseases, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
⁵ Division of Pulmonary Diseases and Intensive Care, La Tour Hospital, Meyrin, Geneva, Switzerland.
⁶ HP2 laboratory, Inserm U1042 unit, University Grenoble Alps, Grenoble, France; EFCR laboratory, Thorax and vessels, Grenoble Alps University Hospital, Grenoble, France.
⁷ Division of Pulmonary Diseases, Geneva University Hospitals (HUG), Geneva, Switzerland; Faculty of Medicine, University of Geneva, Geneva, Switzerland. Electronic address: jean-paul.janssens@hcuge.ch.

PMID: 32243941
DOI: 10.1016/j.chest.2020.02.064

Abstract

Background: Noninvasive ventilation (NIV) is standard of care for chronic hypercapnic respiratory failure, but indications, devices, and ventilatory modes are in constant evolution.

Research question: To describe changes in prevalence and indications for NIV over a 15-year period; to provide a comprehensive report of characteristics of the population treated (age, comorbidities, and anthropometric data), mode of implementation and follow-up, devices, modes and settings used, physiological data, compliance, and data from ventilator software.

Study design and methods: Cross-sectional observational study designed to include all subjects under NIV followed by all structures involved in NIV in the Cantons of Geneva and Vaud (1,288,378 inhabitants).

Results: A total of 489 patients under NIV were included. Prevalence increased 2.5-fold since 2000 reaching 38 per 100,000 inhabitants. Median age was 71 years, with 31% being > 75 years of age. Patients had been under NIV for a median of 39 months and had an average of 3 ± 1.8 comorbidities; 55% were obese. COPD (including overlap syndrome) was the most important patient group, followed by obesity hypoventilation syndrome (OHS) (26%). Daytime Paco₂ was most often normalized. Adherence to treatment was satisfactory, with 8% only using their device < 3.5 h/d. Bilevel positive pressure ventilators in spontaneous/timed mode was the default mode (86%), with a low use of autotitrating modes. NIV was initiated electively in 50% of the population, in a hospital setting in 82%, and as outpatients in 15%.

Interpretation: Use of NIV is increasing rapidly in this area, and the population treated is aging, comorbid, and frequently obese. COPD is presently the leading indication followed by OHS.

Trial registry: ClinicalTrials.gov; No.: NCT04054570; URL: www.clinicaltrials.gov.

Keywords: COPD; compliance; hypoventilation syndrome; monitoring; noninvasive ventilation; obesity; prevalence; ventilator settings.

Publication types

Observational Study
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Aged, 80 and over
Cross-Sectional Studies
Female
Home Care Services
Humans
Male
Middle Aged
Noninvasive Ventilation*
Obesity Hypoventilation Syndrome / therapy*
Patient Compliance*
Patient Selection*
Pulmonary Disease, Chronic Obstructive / therapy*
Switzerland

Associated data

ClinicalTrials.gov/NCT04054570